{
    "clinical_study": {
        "@rank": "38474", 
        "arm_group": [
            {
                "arm_group_label": "Proflex\u00ae Mesh", 
                "arm_group_type": "Experimental", 
                "description": "Device: Partially absorbable lightweight mesh Intervention: Mesh implantation"
            }, 
            {
                "arm_group_label": "Marlex\u00ae Mesh", 
                "arm_group_type": "Active Comparator", 
                "description": "Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation"
            }
        ], 
        "brief_summary": {
            "textblock": "Proflex\u00ae Mesh (partially absorbable mesh, Korea) and Marlex\u00ae Mesh (heavyweight mesh) will be\n      used for inguinal hernia repair to compare the safety and efficacy (pain score, quality of\n      life)of two devices at 3 months follow-up."
        }, 
        "brief_title": "Comparative Study of Safety and Efficacy of Heavyweight and Partially Absorbable Mesh in Inguinal Hernia Repair", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hernia, Inguinal", 
        "condition_browse": {
            "mesh_term": [
                "Hernia", 
                "Hernia, Inguinal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male patients >=20 years =<85 years old\n\n          2. Patients with Unilateral hernia\n\n          3. Patients without previous operations in lower part of abdomen\n\n          4. Patients capable to understand the explanation about purpose and method of the trial,\n             and write an Informed Concent Form\n\n          5. Patients capable to participate during the period of the trial\n\n        Exclusion Criteria:\n\n          1. Previous hernia repair at the same site\n\n          2. Incarcerated hernia\n\n          3. Strangulated hernia\n\n          4. Patients to whom and open surgery cannot be indicated\n\n          5. Previous urological surgery\n\n          6. Immune incompetence of patient: AIDS, vesical fibrosis, etc.\n\n          7. Patients with AIHD or patients who take immunosuppressive drugs\n\n          8. Patients with liver disease (ASL, AST \u2265 normal value by more than 3 times)\n\n          9. Patients with kidney disease (creatinine>2.0mg/dL)\n\n         10. Patients on anti-coagulants\n\n         11. Patients with severe systematic disease\n\n         12. Patients with malignant tumor\n\n         13. Patients with infection or with the predicted problem of surgery site healing\n\n         14. Participation in another clinical study within the last 30 days\n\n         15. Patients whose participation is considered inappropriate according to other except\n             above mentioned clinical condition"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877122", 
            "org_study_id": "MS1-1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Proflex\u00ae Mesh", 
                "description": "Implantation of mesh in the incision of inguinal area", 
                "intervention_name": "Proflex\u00ae Mesh Mesh implantation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Marlex\u00ae Mesh", 
                "intervention_name": "Marlex\u00ae Mesh Implant", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 12, 2013", 
        "location": {
            "contact": {
                "email": "lapkoy@samyang.com", 
                "last_name": "Jin"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samyang Biopharmaceuticals"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Eulji Medical Center", 
            "last_name": "Yeonsoo Chang, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pain score (10-point Visual Analogue Scale)", 
            "safety_issue": "No", 
            "time_frame": "Day90 after operation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Samyang Biopharmaceuticals Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samyang Biopharmaceuticals Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}